WASHINGTON, May 16 (TNSFR) -- The Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA) is announcing a request for information regarding a regulatory science initiative. The aims of the initiative are to advance biomarker validation through the compilation of data from multiple sources and through a specific pilot project focused on aggregating data for biomarkers of drug-induced kidney injury. The purpose of this notice is to inform the public of the aims of . . .

Click here for more information about our products